Ziarco is an independent, clinical stage biotechnology company progressing novel & differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery Ziarco’s approach is to advance our programmes in therapeutic indications where evidence of differentiation can be clearly demonstrated at early times during clinical development